Advertisement

Topics

Cell Medica Acquires WT1 Cancer Immunotherapy from Cell and Gene Therapy Catapult

02:00 EDT 20 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Acquisition transfers rights for WT1-TCR cell therapy from CGT Catapult to Cell Medica Collaboration for development, scale-up and manufacturing also established Cell Medica today announced the acquisition of Catap...

Other Sources for this Article

For further information please contact:
Cell Medica
Gregg Sando, CEO
Gregg.Sando@cellmedica.co.uk
+44 (0)20 7554 4070
or
FTI Consulting for the CGT Catapult
Con Franklin
+44 (0) 203 319 5560
con.franklin@fticonsulting.com
or
Michael Trace
+44 (0) 203 319 5674
michael.trace@fticonsulting.com

NEXT ARTICLE

More From BioPortfolio on "Cell Medica Acquires WT1 Cancer Immunotherapy from Cell and Gene Therapy Catapult"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...